Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vertex Pharmaceuticals Incorporated VRTX
$346.08
-$4.27 (-1.23%)
На 18:00, 12 мая 2023
-18.68%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
89161926880.00000000
-
week52high
354.46
-
week52low
240.25
-
Revenue
8930700000
-
P/E TTM
27
-
Beta
0.48823500
-
EPS
12.57000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Neutral | Neutral | 17 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 08 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 05 авг 2022 г. |
| Barclays | Overweight | Overweight | 05 авг 2022 г. |
| Piper Sandler | Neutral | Neutral | 26 июл 2022 г. |
| JP Morgan | Overweight | Overweight | 24 окт 2022 г. |
| Wells Fargo | Overweight | Overweight | 28 окт 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 28 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 28 окт 2022 г. |
| Barclays | Overweight | Overweight | 28 окт 2022 г. |
| Argus Research | Buy | Buy | 17 ноя 2022 г. |
| Jefferies | Hold | Buy | 19 дек 2022 г. |
| Piper Sandler | Neutral | Neutral | 19 янв 2023 г. |
| Canaccord Genuity | Hold | 18 янв 2023 г. | |
| SVB Leerink | Outperform | Market Perform | 17 янв 2023 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| LEIDEN JEFFREY M | D | 75423 | 3578 | 02 февр 2023 г. |
| WAGNER CHARLES F JR | A | 72890 | 9440 | 01 февр 2023 г. |
| WAGNER CHARLES F JR | A | 63450 | 10262 | 01 февр 2023 г. |
| WAGNER CHARLES F JR | A | 53188 | 10324 | 01 февр 2023 г. |
| Tatsis Ourania | A | 70412 | 7866 | 01 февр 2023 г. |
| Tatsis Ourania | A | 62546 | 10262 | 01 февр 2023 г. |
| Tatsis Ourania | A | 52284 | 6194 | 01 февр 2023 г. |
| Sachdev Amit | A | 79752 | 7866 | 01 февр 2023 г. |
| Sachdev Amit | A | 71886 | 8210 | 01 февр 2023 г. |
| Sachdev Amit | A | 63676 | 10324 | 01 февр 2023 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 7306250 | -69443 | 31 авг 2020 г. |
| Vanguard 500 Index Fund | 5327500 | -18366 | 31 авг 2020 г. |
| Invesco QQQ Trust | 2957510 | 45462 | 31 авг 2020 г. |
| SPDR S&P 500 ETF | 2734630 | -12948 | 31 авг 2020 г. |
| Fidelity Contrafund | 6500680 | 34701 | 31 июл 2020 г. |
| American Funds Growth Fund of America | 7882980 | -328485 | 30 июн 2020 г. |
| T. Rowe Price Blue Chip Growth Fund | 5048310 | -112756 | 30 июн 2020 г. |
| American Funds New Perspective Fund | 3920540 | 200000 | 30 июн 2020 г. |
| Vanguard Health Care Fund | 3342220 | -1268730 | 30 июн 2020 г. |
| T. Rowe Price Growth Stock Fund | 2725040 | -137200 | 30 июн 2020 г. |
Новостная лента
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
The Motley Fool
11 мая 2023 г. в 14:00
Investors will love Johnson & Johnson's commitment to dividend payments. Vertex Pharmaceuticals already delivers billion-dollar earnings -- and new programs could further lift growth.
This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?
The Motley Fool
11 мая 2023 г. в 09:05
Vertex Pharmaceuticals' cystic fibrosis drugs are extending the lives of child and adult patients. Now, babies as young as one month old may benefit from one of the company's treatments.
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock
The Motley Fool
06 мая 2023 г. в 13:00
Warren Buffett has a laser-like focus on owning companies with limited competition, stellar management, and sustainable profits. The rare disease specialist Vertex Pharmaceuticals ticks all of these boxes, despite operating in a fiercely competitive industry.
2 Potentially Explosive Stocks to Buy in May
The Motley Fool
04 мая 2023 г. в 05:32
Stag Industrial is a real estate investment trust that benefits from e-commerce expansion. Vertex Pharmaceuticals is a leader in cystic fibrosis therapies.
Here's 1 Magnificent Reason to Buy Vertex Pharmaceuticals Stock
The Motley Fool
03 мая 2023 г. в 10:15
It is the only company that has succeeded in treating the underlying causes of cystic fibrosis. The biotech is still working in this area, and given its track record, it's hard to bet against it.